1078151-34-4

Basic information

• Product Name: 5-(tert-butoxycarbonyl)-3a,4,5,6,7,7a-hexahydrothieno[3,2-c]pyridin-2-ylboronic acid
• Synonyms: 5-(tert-butoxycarbonyl)-3a,4,5,6,7,7a-hexahydrothieno[3,2-c]pyridin-2-ylboronic acid;Thieno[3,2-c]pyridine-5(4H)-carboxylic acid, 2-borono-6,7-dihydro-, 5-(1,1-diMethylethyl) ester;(5-(tert-Butoxycarbonyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)boronic acid
• CAS NO: 1078151-34-4
• Molecular Formula: C₁₂H₁₈BNO₄S
• Molecular Weight: 285.1675
• Mol File: 1078151-34-4.mol

Chemical Properties

• Boiling Point: 474.1±55.0 °C(Predicted)
• Appearance: /
• Density: 1.29±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 8.60±0.20(Predicted)
• CAS DataBase Reference: 5-(tert-butoxycarbonyl)-3a,4,5,6,7,7a-hexahydrothieno[3,2-c]pyridin-2-ylboronic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(tert-butoxycarbonyl)-3a,4,5,6,7,7a-hexahydrothieno[3,2-c]pyridin-2-ylboronic acid(1078151-34-4)
• EPA Substance Registry System: 5-(tert-butoxycarbonyl)-3a,4,5,6,7,7a-hexahydrothieno[3,2-c]pyridin-2-ylboronic acid(1078151-34-4)

Safety Data

• Hazardous Substances Data: 1078151-34-4(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
5-(tert-butoxycarbonyl)-3a,4,5,6,7,7a-hexahydrothieno[3,2-c]pyridin-2-ylboronic acid is used as a synthetic intermediate for the creation of carbon-carbon and carbon-heteroatom bonds, which are crucial in the assembly of complex organic molecules.
Used in Medicinal Chemistry:
In the pharmaceutical industry, 5-(tert-butoxycarbonyl)-3a,4,5,6,7,7a-hexahydrothieno[3,2-c]pyridin-2-ylboronic acid is utilized as a key component in the development of new drugs, owing to its potential to form diverse molecular structures that can interact with biological targets.
Used in Suzuki-Miyaura Coupling Reactions:
5-(tert-butoxycarbonyl)-3a,4,5,6,7,7a-hexahydrothieno[3,2-c]pyridin-2-ylboronic acid is employed as a coupling agent in Suzuki-Miyaura reactions, a type of cross-coupling reaction used to form carbon-carbon bonds between an organoboronic acid and an organohalide or triflate. This reaction is particularly valuable in the synthesis of complex organic molecules, including those with potential pharmaceutical applications.

Upstream product

• 230301-73-2 6,7-dihydro-4H-thieno[3,2-c]-pyridine-5-carboxylic acid tert-butyl ester 

Downstream Products

• 1142947-11-2 tert-butyl 2-(2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-carboxylate 
• 1142946-99-3 tert-butyl 2-(2-{[3-(4-methylpiperazin-1-yl)phenyl]amino}-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-carboxylate 
• 1142947-31-6 2-{2-[4-(2-methyl-imidazol-1-ylmethyl)-phenylamino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}-6,7-dihydro-4H-thieno[3,2-c]pyridine-5-carboxylic acid tert-butyl ester 
• 1142947-94-1 tert-butyl 2-(2-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-carboxylate 

Relevant articles and documents

PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USE AS JANUS KINASE MODULATORS

Provided herein are pyrrolopyrimidine compounds of Formula (I) wherein R1 is a heteroaryl containing at least one S atom, and optionally substituted on a ring carbon by one, two, or three substituents each independently selected from the group consisting of : halo, hydroxyl, nitro, formyl, formamido, cyano, sulfonyl, carboxy, amino, amido, acylamino, carbamoyl, sulphamoyl, alkyl, alkenyl, CF3, ureido, alkynyl, alkoxy, alkanoyl, alkoxycarbonyl, carbaldehyde oxime, N -alkylsulphamoyl, N-alkylcarbamoyl, -OR13R11 or -R13R11; R2 is phenyl or pyridinyl, wherein R2 optionally substituted on a ring carbon by one, two, or three substituents each indenpendently selected from the group consisting of : halo, hydroxyl, cyano, nitro, formyl, formamido, carboxy, sulfonyl, amino, amido, -N- alkyl -amino, carbamoyl, sulphamoyl, CF3, ureido, alkyl, alkenyl, alkynyl, alkoxy, alkanoyl, alkoxycarbonyl, N-alkylsulphamoyl, N-alkylcarbamoyl, -OR11, -OR12R11, or -R12R11; and methods of making and using the same. Such compounds may be used in inflammatory or myeloproliferative disorders. The disclosure also provides for treating cancer.

THIAZOLIDINONE COMPOUNDS, AND METHODS OF MAKING AND USING SAME

Provided herein are thiazolidinone compounds, and methods of making and using the same. Such compounds may be used in inflammatory or immune-mediated disorders. The disclosure provides for treating respiratory or ocular disorders, treating arthritis, or may be used to treat cancer, such as prostate or breast cancer, or multiple myeloma.